Trending

News

Kiadis Pharma and Sanofi to unlock power of natural killer cells in multiple myeloma

Kiadis Pharma and Sanofi to unlock power of natural killer cells in multiple myeloma

Sanofi has struck an exclusive rights deal with Dutch biotech Kiadis focused on combining modified natural killer cells

X

Kiadis Pharma and Sanofi to unlock power of natural killer cells in multiple myeloma

https://pharmaphorum.com/news/sanofi-to-develop/

EU regulators approve AstraZeneca’s Lynparza in pancreatic cancer

EU regulators approve AstraZeneca’s Lynparza in pancreatic cancer

The European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) in pancreatic cancer patients with a certain mutation. Approval in metastatic

X

EU regulators approve AstraZeneca’s Lynparza in pancreatic cancer

https://pharmaphorum.com/news/eu-regulators-approve-astrazenecas-lynparza-in-pancreatic-cancer/

AI health record scanning could identify pancreatic cancer early

AI health record scanning could identify pancreatic cancer early

Artificial intelligence (AI) could hold the key to identifying people at risk of pancreatic cancer early, allowing them

X

AI health record scanning could identify pancreatic cancer early

https://pharmaphorum.com/news/ai-health-record-scanning-could-identify-pancreatic-cancer-early/

FDA approves Pfizer/Merck KGaA’s Bavencio in first line bladder cancer

FDA approves Pfizer/Merck KGaA’s Bavencio in first line bladder cancer

The FDA has approved Pfizer and Merck KGaA’s immunotherapy Bavencio (avelumab) as a first line maintenance therapy in bladder cancer, setting up a rivalry with

X

FDA approves Pfizer/Merck KGaA’s Bavencio in first line bladder cancer

https://pharmaphorum.com/news/fda-approves-pfizer-merck-kgaas-bavencio-in-first-line-bladder-cancer/

Merck & Co’s Keytruda gets new colorectal cancer use after month-long FDA review

Merck & Co’s Keytruda gets new colorectal cancer use after month-long FDA review

It’s barely a month since Merck & Co unveiled trial results showing that cancer immunotherapy Keytruda (pembrolizumab) works in colorectal

X

Merck & Co’s Keytruda gets new colorectal cancer use after month-long FDA review

https://pharmaphorum.com/news/merck-cos-keytruda-gets-new-colorectal-cancer-use-after-month-long-fda-review/

NICE green lights Roche’s Rozlytrek for NTRK tumours

NICE green lights Roche’s Rozlytrek for NTRK tumours

The UK’s National Institute for Health and Care Excellence (NICE) has cleared Roche’s Rozlytrek for NTRK fusion-positive solid

X

NICE green lights Roche’s Rozlytrek for NTRK tumours

https://pharmaphorum.com/news/nice-green-lights-roches-rozlytrek-for-ntrk-tumours/

Gilead to acquire half of cancer biotech Pionyr for $275m

Gilead to acquire half of cancer biotech Pionyr for $275m

Gilead has announced it is to acquire nearly half of the cancer drug biotech Pionyr, with an exclusive

X

Gilead to acquire half of cancer biotech Pionyr for $275m

https://pharmaphorum.com/news/gilead-to-acquire-cancer-biotech-pionyr/

Medical charities “slipping through cracks” of UK pandemic support

Medical charities “slipping through cracks” of UK pandemic support

Charities have already been hit hard by the coronavirus pandemic and lockdown, and Cancer Research UK says it

X

Medical charities “slipping through cracks” of UK pandemic support

https://pharmaphorum.com/news/medical-charities-slipping-through-cracks-of-uk-pandemic-support/

Merck KGaA’s ATR cancer drug cleared for further trials after phase 1 trial success

Merck KGaA’s ATR cancer drug cleared for further trials after phase 1 trial success

Merck KGaA’s ATR inhibitor cancer drug has been cleared for further clinical trials after it showed encouraging activity in

X

Merck KGaA’s ATR cancer drug cleared for further trials after phase 1 trial success

https://pharmaphorum.com/news/mercks-atr-cancer-drug-cleared-for-clinical-trials-after-phase-1-trial-success/

1 2 3 4 5 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com